Product Description:
Perjeta 420 mg/14 mL is an advanced cancer treatment solution containing Pertuzumab, a monoclonal antibody specifically developed for HER2-positive breast cancer patients. Manufactured by Roche, Perjeta is often used in combination with trastuzumab (Herceptin) and chemotherapy to provide a powerful and targeted therapy for both early and metastatic breast cancer. As a targeted therapy, Perjeta blocks the HER2 receptor, which is overexpressed in certain aggressive breast cancers, thereby inhibiting cancer cell growth and improving patient survival rates.
Key Product Details:
- Active Ingredient: Pertuzumab 420 mg/14 mL (30 mg/mL)
- Formulation: Concentrated solution for intravenous (IV) infusion
- Administration: Intravenous infusion under healthcare supervision
- Packaging: 1 vial (14 mL)
- Manufacturer: Roche Pharmaceuticals
Key Benefits of Perjeta 420 mg/14 mL:
- Targeted HER2 Blockade: Perjeta specifically binds to the HER2 receptor, preventing cancer cell proliferation and promoting cell death.
- Enhanced Efficacy: When used in combination with trastuzumab and chemotherapy, Perjeta significantly increases progression-free survival and overall survival in HER2-positive breast cancer patients.
- Effective in Neoadjuvant and Metastatic Settings: Approved for both early-stage and metastatic HER2-positive breast cancer, offering flexible treatment approaches.
- Reduced Risk of Recurrence: Clinical studies have demonstrated that Perjeta, as part of a comprehensive treatment plan, reduces the risk of cancer recurrence in early-stage breast cancer.
Indications – What Is Perjeta Used For?
Perjeta 420 mg/14 mL is prescribed for:
- Neoadjuvant Treatment (Pre-Surgery): For patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer.
- Adjuvant Treatment (Post-Surgery): To reduce the risk of recurrence in HER2-positive early breast cancer patients with a high risk of relapse.
- Metastatic Breast Cancer: For patients with HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel.
How Does Perjeta 420 mg/14 mL Work?
Perjeta (Pertuzumab) works as a HER2-targeted therapy, binding to a different site on the HER2 receptor compared to trastuzumab. This dual blockade mechanism (Pertuzumab + Trastuzumab) prevents HER2 dimerization, blocking cell signaling pathways that lead to cancer growth. This combined action results in superior tumor suppression and better treatment outcomes.
Dosage and Administration:
- Loading Dose: 840 mg as an intravenous infusion over 60 minutes.
- Maintenance Dose: 420 mg every three weeks as an intravenous infusion over 30-60 minutes.
- Administered under the supervision of a healthcare professional experienced in cancer therapies.
Safety Information:
- Cardiac Monitoring Required: Perjeta can affect heart function. LVEF (Left Ventricular Ejection Fraction) monitoring is essential during treatment.
- Infusion Reactions: Patients may experience chills, fever, nausea, or fatigue during infusion.
- Pregnancy Warning: Perjeta can cause fetal harm; pregnancy should be avoided during and for 7 months after the last dose.
- Side Effects: Diarrhea, nausea, alopecia, fatigue, neutropenia, rash.
Why Choose Perjeta 420 mg/14 mL?
Perjeta is globally recognized as a gold-standard therapy for HER2-positive breast cancer, offering a synergistic effect when combined with trastuzumab and chemotherapy. It is proven to extend survival and reduce recurrence risk in aggressive breast cancer cases.
Storage Conditions:
- Store at 2°C to 8°C (refrigerated).
- Do not freeze or shake. Protect from light.
Buy Perjeta 420 mg/14 mL Online:
Secure your supply of Perjeta 420 mg/14 mL from trusted sources. We offer genuine Roche products with global shipping options. Our expert team ensures timely delivery, ensuring uninterrupted access to this life-saving treatment for HER2-positive breast cancer.
Değerlendirmeler
Henüz değerlendirme yapılmadı.